Company intelligence
LucidQuest
Accelerate your success with decision-grade intelligence and wargames for biopharma, digital health, and investors
About LucidQuest
LucidQuest helps biopharma, healthtech, and investors make faster, higher-confidence decisions with decision-grade intelligence. We combine: Primary intelligence (KOL, payer, patient, and market stakeholder research) Real-time conference coverage (previews, live tracking, and strategic debriefs across major congresses) AI-powered, human-in-the-loop wargames and workshops to test strategy under uncertainty Tech-enabled monitoring and analysis supported by proprietary tools Our work supports high-stakes choices from R&D through commercialization, plus investment diligence, translating complex signals into clear recommendations teams can act on. We bring deep scientific training and hands-on experience across biopharma and healthcare technology, including AI and digital health, and we operate globally through an expert network spanning regions and therapy areas. Let’s connect if you need primary intelligence, congress coverage, a competitive wargame, or strategic advisory. Specialties: strategy consulting, strategic and competitive intelligence, business strategy, strategic marketing, scenario planning, venture capital, digital health, mHealth, eHealth, Internet of Everything, vaccines, immunotherapies, gene therapy, cell therapy, cardiovascular, HIV/AIDS, biofinance, biotechnology, pharmaceuticals, business and financial modelling, patient centricity, respiratory and infectious diseases, oncology, pre-clinical and clinical development, molecular biology, immunology, social media
Verified activity
Signals from LucidQuest
13 published signals
Products & Services
LucidQuest runs LOE scenarios with teams before biosimilar or generic lands to simulate pressure and make decisions.
Reported by Dr. Timos Papagatsias
Products & Services
LucidQuest built patentcliffclock.com to show real-time patent expiration dates and ticking clocks.
Reported by Dr. Timos Papagatsias
Presence & Recognition
LucidQuest announced the Download: our 35 Innovators Under 35 this year
Reported by Dr. Timos Papagatsias
Legal & Regulatory
LucidQuest announced that DKS Investors have an opportunity to lead the DICK’S Sporting Goods, Inc. Securities Fraud Lawsuit with SBS Law.
Reported by Dr. Timos Papagatsias
Research & Knowledge
LucidQuest received comments from Garmin regarding possible CIRQA Smart Ring sizes in filings.
Reported by Dr. Timos Papagatsias
Presence & Recognition
LucidQuest submitted an application for gene therapy for Huntington's disease to Zacks Investment Research.
Reported by Dr. Timos Papagatsias
Products & Services
LucidQuest announced that Mindsec added DORA and GDPR Readiness to its EU Compliance Suite.
Reported by Dr. Timos Papagatsias
Products & Services
LucidQuest launched GPT Image 2.5, a new version of the GPT image generation model.
Reported by Dr. Timos Papagatsias
Research & Knowledge
LucidQuest published the latest Respiratory Strategic Roundup covering developments from 31 July to 3 September 2026, highlighting a shift toward differentiation in respiratory treatment markets.
Reported by LucidQuest
Research & Knowledge
LucidQuest published its H1 2026 analysis across 14 therapy areas revealing a fragmented landscape in which app numbers, digital capabilities, and clinical maturity are developing at varying rates.
Reported by LucidQuest
Research & Knowledge
LucidQuest published the H1 2026 Healthcare and Pharma Trends Report examining developments across 14 major therapy areas and healthcare sectors.
Reported by LucidQuest
Research & Knowledge
LucidQuest published the latest Obesity Strategic Roundup covering developments from 28 July to 31 August 2026, exploring broader competition across oral obesity drugs, regional access, pricing, supply, and next-generation therapies.
Reported by LucidQuest
Capital & Finance
LucidQuest announced that the Advanced Therapy Medicinal Products Market is expected to reach US$121.81 billion by 2034
Reported by Dr. Timos Papagatsias